25 Sep 2012 16:19
e-Therapeutics plc ("e-Therapeutics" or "the Company")
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
The Company was advised on 24 September 2012 that Novotech Investment Limited (NIL), a company that Professor Malcolm Young (CEO) is a Director of and in which he has options to subscribe for ordinary shares, hadtransferred 410,059 ordinary shares of 0.1p each to a nominee company, Brewin Dolphin Nominees Limited. The transfer does not result in a change to Professor Young's total beneficial interest which remains the same at 20,620,482 shares representing 14.92% of the total voting rights (of which 10,310,241 shares are held by Professor Young and 10,310,241 shares are held by Professor Young's wife). Professor Young also has an indirect holding of a further 428,512 shares relating to interests that he holds in NIL and Novotech Syndicate LLP.
25 September 2012
Contacts
e-Therapeutics plc Tel: +44 (0)79 0991 5068
Daniel Elger
Panmure Gordon (UK) Limited Tel: +44 (0)20 7459 3600
Fred Walsh / Grishma Patel / Hannah Woodley